Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M170,395Revenue $M44,033Net Margin (%)10.0Z-Score3.4
Enterprise Value $M182,753EPS $1.5Operating Margin %14.4F-Score6
P/E(ttm))31.4Cash Flow Per Share $6.3Pre-tax Margin (%)12.6Higher ROA y-yY
Price/Book3.510-y EBITDA Growth Rate %2.2Quick Ratio1.5Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-6.3Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %9.5ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)8.9Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,922ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 58.913%Add 3456.04%126,844
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 58.913%New holding, 86800 sh.86,800
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 58.913%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 58.913%Reduce -10.01%35,960,137
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 58.913%Reduce -21.54%1,755,082
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 58.913%Sold Out0
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 58.919%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 58.919%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 58.919%New holding, 3567 sh.3,567
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 58.919%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 58.919%Reduce -18.11%39,959,196
MRKVanguard Health Care Fund 2014-03-31 Reduce-0.15%$49.49 - $57.47
($54)
$ 58.919%Reduce -2.58%35,616,848
MRKGeorge Soros 2014-03-31 Sold Out -0.06%$49.49 - $57.47
($54.09)
$ 58.919%Sold Out0
MRKJohn Hussman 2014-03-31 Sold Out -0.01%$49.49 - $57.47
($54)
$ 58.919%Sold Out0
MRKGeorge Soros 2013-12-31 Buy 0.06%$45.09 - $50.18
($47.86)
$ 58.9123%New holding, 150000 sh.150,000
MRKRuane Cunniff 2013-12-31 Buy $45.09 - $50.18
($47.86)
$ 58.9123%New holding, 4075 sh.4,075
MRKJean-Marie Eveillard 2013-12-31 Reduce-0.16%$45.09 - $50.18
($47.86)
$ 58.9123%Reduce -98.76%14,050
MRKLeon Cooperman 2013-12-31 Sold Out -0.15%$45.09 - $50.18
($47.86)
$ 58.9123%Sold Out0
MRKCharles Brandes 2013-12-31 Reduce-0.14%$45.09 - $50.18
($47.86)
$ 58.9123%Reduce -8.39%2,476,201
MRKJean-Marie Eveillard 2013-09-30 Reduce-0.16%$46.55 - $48.58
($47.88)
$ 58.9123%Reduce -49.6%1,134,041
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK George Soros 2014-06-3086,80000.04New Buy
MRK Joel Greenblatt 2014-06-30126,84400.09+3456.04%
MRK Ruane Cunniff 2014-06-304,60900+4.54%
MRK James Barrow 2014-06-3022,793,2070.781.8+0.24%
MRK Mario Gabelli 2014-06-30160,3160.010.05
MRK Prem Watsa 2014-06-3012,00000.05
MRK Charles Brandes 2014-06-302,434,5310.081.7-0.68%
MRK Vanguard Health Care Fund 2014-06-3033,889,9481.165.2-4.85%
MRK Dodge & Cox 2014-06-3035,960,1371.232-10.01%
MRK Jean-Marie Eveillard 2014-06-301,755,0820.060.25-21.54%
MRK David Dreman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2014-08-11Sell10,058$572.49view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2014-08-04Sell28,669$56.643.14view
FRAZIER KENNETH CChairman, President & CEO 2014-07-10Sell9,987$58.030.67view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.16-1.25view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.16-1.25view
Deese Willie AExe V-P & Pres. MMD 2014-06-27Sell72,290$58.260.27view
FRAZIER KENNETH CChairman, President & CEO 2014-06-10Sell9,985$58.060.62view
Schechter Adam HEVP & Pres-Global Human Health 2014-05-14Sell10,527$55.914.49view
FRAZIER KENNETH CChairman, President & CEO 2014-05-09Sell10,220$556.22view
FRAZIER KENNETH CChairman, President & CEO 2014-04-10Sell10,047$57.242.06view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
      UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
      U.S. Markets Regain Losses from Last Week Jul 14 2014 
      Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
      U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
      Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
      Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
      Wrong Marketing Lesson by Big Pharma May 03 2014 
      Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
      Bill Nygren Comments on Merck Apr 10 2014 


      More From Other Websites
      Washington Post Off Base In Critiquing Pharma Efforts In Ebola Aug 18 2014
      Biotech Leader Gilead Sciences Scores Sovaldi Win Aug 15 2014
      Gilead Wins Sovaldi Dispute With Roche, U.K. Nod Aug 15 2014
      MERCK & CO. INC. Financials Aug 15 2014
      Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus... Aug 15 2014
      Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed Aug 15 2014
      Merck's Insomnia Drug Belsomra Approved by the FDA Aug 14 2014
      [video] Pfizer and Merck Receive Key Regulatory Approvals Aug 14 2014
      US STOCKS-Wall St rises after Putin comments ease Ukraine worries Aug 14 2014
      US STOCKS-Wall St edges up after Putin comments, Cisco falls Aug 14 2014
      US STOCKS-Wall St edges up after Putin comments, Cisco falls Aug 14 2014
      Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes... Aug 14 2014
      Why Pfizer (PFE) Stock Is Up Today Aug 14 2014
      US STOCKS-Futures tick up ahead of jobless claims data Aug 14 2014
      US STOCKS-Futures tick up ahead of jobless claims data Aug 14 2014
      The F.D.A. Approves a Pill to Help People Stay Asleep Aug 13 2014
      Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP... Aug 13 2014
      FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia Aug 13 2014
      FDA approves new sleeping drug from Merck Aug 13 2014
      FDA approves new sleeping drug from Merck Aug 13 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide